Last update 08 May 2025

RNRs x Pol III x RNA polymerase II

Basic Info

Related Targets
RNRsPol IIIRNA polymerase II

Related

1
Drugs associated with RNRs x Pol III x RNA polymerase II
Fludarabine Phosphate
Target
Pol III x RNA polymerase II x RNRs
Mechanism
DNA polymerase III inhibitors [+2]
Active Org.
National Cancer InstituteNational Cancer Institute [+11]
Originator Org.
Southern Research InstituteSouthern Research Institute
Active Indication
Lymphoma [+111]
Inactive Indication
Acute Erythroblastic Leukemia [+127]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date18 Apr 1991
1,565
Clinical Trials associated with RNRs x Pol III x RNA polymerase II
NCT06677710
/ SuspendedPhase 1
A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
100 Clinical Results associated with RNRs x Pol III x RNA polymerase II
Login to view more data
100 Translational Medicine associated with RNRs x Pol III x RNA polymerase II
Login to view more data
0 Patents (Medical) associated with RNRs x Pol III x RNA polymerase II
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free